Thugmuffin
3 years ago
$HBRM Herborium® Enters $220Billion Digital Content MarketPress Release | 05/10/2022
Houston, May 10, 2022 (GLOBE NEWSWIRE) -- Houston, Texas, 05/10/2022. Herborium Group, Inc. (OTC Pink: HBRM), a Botanical Therapeutics Company and the provider of unique, all botanical medicinal, beauty and wellness products with a clinically validated records of efficacy and safety, announced today that it officially commenced its transition into “Content Plus Product Company” initially previewed in the Company’s February 28th Shareholders Update Letter
Covid Pandemic and following economic and social changes accelerated new healthcare, consumer and technology trends resulted in changing landscape of the e commerce. With 21% growth of on line beauty business since 2018; and over 75% of women and over 55% of men purchasing they selfcare products on line, Herborium expansion of its platform opens a new growth opportunities for the Company.
Simplifying buying on-line, curating purchasing decisions through personalizing regimens of natural self-care and beauty, individualizing diagnosis within healthcare, wellness and beauty concerns and curating unique integrated natural solutions easily accessible by consumers and service providers, positions the Company as a highly competitive and innovative part of the $230Billion digital content market
To develop its innovative technology Herborium partnered with ADRECOM INC. a innovative, technology company focused on development and application of AI (Artificial Intelligence). Herborium Self-Care platform is to integrate not only Herborium products, expertise, and content but also those of qualified partners to provide the most comprehensive, multi-facet hosting and delivery digital tool in natural selfcare and beauty.
In addition, due to Herborium unique expertise, the new platform will provide forum for consumers and professionals seeking natural alternatives to serious self-care concerns (in the first stage focused on skin health) unanswered by traditional providers.
Finally- the innovative technology platform shall allow the Company to establish
a Consortium of selected natural products and know-how partners that together provide one of a kind, comprehensive, easy to use and friendly to access one stop shopping, treatments, counseling, advisement and curated consumer forum in the highly thought after natural wellness and beauty space.
From business perspective this New Model allows Herborium to realize multiple revenues streams, significantly expand its market reach, increase consumer satisfaction and loyalty, and create additional shareholders value trough revenues growth and potential for further partnerships and acquisitions.
The Platform and Consortium is expected to launch in a Fourth Quarter of 2022.
About Herborium Group, Inc.
Herborium Group, Inc., a botanical therapeutics company that develops, license and markets proprietary, botanical based medicinal and wellness products to consumers and healthcare professionals. The Company business model focuses on emerging market opportunities spearheaded by the growth of a new market sector located between high-cost, high-risk, ethical pharmaceuticals and commoditized classic nutraceuticals (supplements). The Company uses clinical validation and a proactive regulatory strategy based on the FDA Guidance for Industry: Botanical Drug Products to establish and maintain a differential advantage. Herborium has secured a pipeline of botanical ingredients based products in the areas of dermatological needs, wellness and energy, women’s health and selected sexual disorders and has built the versatile, technologically advanced, interactive content platform to support consumer needs. Herborium Group sells its products in the United States, the United Kingdom, and continental Europe through a network of distributors, specialty retailers, and e-commerce. For more information, please visit www.herborium.com, www.acnease.com, www.acnease.fr and www.acneasesp.com
Safe Harbor Statement: This release contains forward-looking statements with respect to the results of operations and business of Herborium Group, Inc., which involves risks and uncertainties. The Company's actual future results could materially differ from those discussed. The Company intends that such statements about the Company's future expectations, including future revenues and earnings, and all other forward looking statements be subject to the "Safe Harbors" provision of the Private Securities Litigation Reform Act of 1995.
Attachment
logo PR
Herborium Group, Inc.
CustomerService@Herborium.com ; Investorrelations@Herborium.com
Thugmuffin
3 years ago
$NDEV Novus Releases Its First Quarter of 2022 ReportPress Release | 05/10/2022
Miami, Florida--(Newsfile Corp. - May 10, 2022) - Novus Acquisition and Development, Corp. (OTC Pink: NDEV), through its wholly-owned subsidiary WCIG Insurance Services, Inc., is a hybrid health insurance carrier and, the nation's first health carrier offering cannabis that is included in health plans for recreational and medicinal users, announced today its First Quarter Report and accomplishments.
Cannot view this image? Visit: https://orders.newsfilecorp.com/files/8812/123244_975456e4948c08ce_001.jpg
Image Logo
To view an enhanced version of this graphic, please visit:
https://orders.newsfilecorp.com/files/8812/123244_975456e4948c08ce_001full.jpg
As the Company focuses to build back pre-pandemic growth percentages we continue to identify opportunities with new regulatory elements that are currently favoring our business strategy. We had continued growth in:
Financial Highlights
No Dilution: No common stock was issued in the last four quarters. All third-party vendors receiving stock from the treasury are subject to a mandatory leak out of securities which are 15% of the average daily trading volume over the last 30 days.
Three Month Gross Revenue Increase: Gross Revenue increased $9,244 or 14.56% to $72,725 for the three months ended March 31, 2022, as compared to $63,481 for the three months ended March 31, 2021.
Three Month Net Revenue Increase: Net Revenue, increased from $21,426 to $26,999 an increase of 26 % or $5,573 on March 31, 2022, as compared to three months ended March 31, 2021.
Profit Margin: On March 31, 2022, the Company demonstrated a 37% profit margin pricing structure in its business model an increase of 3% as compared to March 31, 2021.
Shareholder Equity Increase: An increase of $48,439 or 3.27% which is $1,527,225 on March 31, 2022, from $1,478,786 March 31, 2021.
Cash and Cash Equivalents Increase: Moderate increase to $169,299 on March 31, 2022, or 5.8%, from $160,020 for the same period ended March 31, 2021.
InsurTech Platform
InsurTech platforms is a disruptive and innovative technology that sells direct to consumers who have employer-sponsored health plans. These platforms sell health policies on an ala carte basis as opposed to one-size-fits-all health plans.
To gain entry on these platforms is costly and time-consuming, so we sought to find a partner who already had a presence on one or more of these platforms, in return, we would share policy sales. After lengthy negotiations with many third-party partnerships, their economic proposals proved not to be a viable option for the Company.
This decision was based on two factors, the cost of sharing revenue was extremely high by as much as 30%-45%, the other factor. was favoring regulatory changes regarding cannabis in the workplace and Veteran benefits. Consequently, management decided to take the time and expense of getting on these platforms directly to bypass this capital outlay.
Industry Trends and Regulatory Landscape
Changes in the regulatory landscape were quite fortunate with key factors in shaping the cannabis health plan marketplace.
Significant changes in the fourth quarter that is benefiting Novus were the Compassionate Care Act: where employees are protected from termination for using medical cannabis, this leads the way to employer-sponsored health plans. Opioid Settlement Framework: state Attorney Generals settling with carrier and big pharma in $45 billion compensatory damages, rehabilitation, and opioid diversion programs which Novus proposes its health plans. Most notably,
Rising Recreational Cannabis Taxation: especially in California, taxation is as high as 37% prompting recreational users in getting their state cannabis cards and joining our health plan to get the medicinal tax rate which is 50% less than the rec tax rate.
Accommodating American Veterans
Novus has prepared for the bipartisan legislation that allows cannabis benefits to 19 million Veterans. Amongst the numerous regulations are:
The Veterans Cannabis Use for Safe Healing Act: Prohibits the Department of Veterans Affairs (VA) from denying VA benefits due to participation in a state-approved cannabis program(s).
The VA Medicinal Cannabis Research Act: VA to carry out a series of clinical trials on the health effects cannabis can have on Veterans who suffer from chronic pain and PTSD.
The Common Sense Reform for Veterans, Small Businesses, and Medical Professionals Act: Allows the VA to prescribe medical cannabis to Veterans and create a safe harbor for financial institutions and other businesses.
The Veterans Medical Marijuana Safe Harbor Act: Provide and implement guidance for Veterans on medical cannabis. Lastly, the bill requires the VA to report on the impacts of medical cannabis on Veterans' pain and the relationship between state-approved medical cannabis treatment programs.
The Fully Informed Veteran Act: Requires the VA to authorize VA physicians and healthcare providers permission to educate Veterans on participating in state-legal cannabis programs.
v. California SB1186 Medicinal Patients' Right of Access:
State bill SB 1186 will help to dramatically expand safe access to medical cannabis throughout the state. Once passed this will dramatically increase Novus provider network from dispensaries to doctor's offices, urgent care facilities, hospitals, and managed healthcare. Just like the Employee Compassionate Care Act, there will be states following suit on similar legislation.
More Cultivators /Manufacturing Are Becoming Providers
Many cultivators are adopting selling direct-to-consumer and are using delivery platforms to sell their products regionally, opening up a new segment in our provider network. One of Novus' providers Budee, has one such platform that covers the entire state of California with four distribution centers and 800 deliveries per day. This gives Novus the ability to consolidate its provider network where policyholders can order from the digital platforms of their choice and get their product(s) within an hour.
Conclusion
Being first to market as a health insurance carrier has given us an increased market share of our infrastructure, combined with favorable changes in state and federal regulations, solidifying the scope of our business model profoundly.
Novus is in a virtuous position with cannabis and health insurance industries demonstrated to be recession-proof. We will remain a receivable-based business limiting overhead, and once the policyholder is procured, their policy contribution will go directly to the Company's Net Asset Value, benefiting our shareholders.
Research Novus:
As a carrier, the insurance industry relies on two key indicators to measure value and performance. The Benefit Monetization Ratio is defined as a total number of policies, monetized annually as an Asset, then, is offset by the operating cost ratio then computed to the Balance Sheet as Net Asset Value. See how insurance companies are valued: Click Here
Financial Filings: Click Here
Quote: Click Here
Website: Click Here
Investor's Page: Click Here
About Novus
Novus Acquisition & Development Corp. (NDEV), through its subsidiary WCIG Insurance, Services, Inc. provides health insurance and related insurance solutions within the wellness and medical marijuana industries in states where legal programs exist. Novus has developed its infrastructure within many lines of the insurance business such as health, life, and fixed annuities. As a carrier Novus relies on two key indicators to measure value and performance. The Benefit Monetization Ratio is defined as a total number of policies, monetized annually, which is offset by the operating cost ratio which is a Balance Sheet line item computed as Net Asset Value.
Novus' medical cannabis benefits package will work as outside developers and will not cultivate, handle, transport grow, extract, dispense, put up for sale, put on the market, vend, deliver, supply, circulate, or trade cannabis or any substances that violate the United States law or the Controlled Substances Act, nor does it intend to do so in the future and will continue to follow state and federal laws. The statements made about specific products have not been evaluated by the United States Food and Drug Administration (FDA) and are not intended to diagnose, treat, cure, or prevent disease. All information provided on these press releases, or any information contained on or in any product label or packaging is for informational purposes only and is not intended as a substitute for advice from your physician or other health care professional. All cannabis transaction is solely between the state-licensed dispensary and the registered patient.
The state laws conflict with the federal Controlled Substances Act. The current administration has effectively stated that it is not an efficient use of resources to direct federal law enforcement agencies to prosecute those lawfully abiding by state-designated laws, allowing the use and distribution of medical marijuana. Changes in consolidation may affect the provider network. However, there is no guarantee that the current administration, nor any future administration, will not change this policy and decide to enforce the federal laws strongly. Any such change in the federal government's enforcement of current federal laws could cause significant financial changes. While we do not intend to harvest, distribute, or sell cannabis or cannabis-related products, we may be harmed by a change in enforcement by federal or state governments.
Forward-Looking Statements
This release includes forward-looking statements, which are based on certain assumptions and reflect management's current expectations. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. Some of these factors include: general global economic conditions; general industry and market conditions and growth rates; uncertainty as to whether our strategies and business plans will yield the expected benefits; increasing competition; availability and cost of capital; the ability to identify and develop and achieve commercial success; the level of expenditures necessary to maintain and improve the quality of services; changes in the economy; changes in laws and regulations, includes codes and standards, intellectual property rights, and tax matters; or other matters not anticipated; our ability to secure and maintain strategic relationships and distribution agreements. Novus disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. Additionally, this press release that is not statements of historical fact may be considered to be forward-looking statements. Written words, such as "may," "will," "expect," "believe," "anticipate," "estimate," "intends," "goal," "objective," "seek," "attempt," or variations of these or similar words, identify forward-looking statements. By their nature, forward-looking statements and forecasts involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the near future.
Investor Contact Information
855-228-7355
Email: info@getnovusnow.com
AskMuncher
3 years ago
$NDEV
Novus Cannabis MedPlan Reports Third Quarter 2021 Results
Press Release | 10/29/2021
Novus Acquisition and Development, Corp. (OTC Markets: NDEV), through its wholly-owned subsidiary WCIG Insurance Services, Inc., is a hybrid health insurance entity and, the nations first health carrier offering cannabis in health plans to recreational and medicinal users, today reported its third-quarter financial results for the three months ended September 30, 2021, and update on the progression of its business model.
Employer-Sponsored Health Plans
As Novus comes out from under the COVID crisis were experiencing a breakthrough development in our effort to penetrate Insurance Group Sales in the small to midsize businesses (SMB) market. As SMBs desire to compete and expand, it is essential to attract and retain their talent pool with competitive health benefits, but affordability remains an issue as healthcare costs rise faster than inflation.
According to the Bureau Of Labor Statistics, more than half (57%), of SMB workers did not have employer-sponsored health benefits. The top perks employees seek are employer-sponsored, dental, vision, and Health Savings Account (HSA).
Novus cannabis benefits packages fit into this niche, with the desirability of cannabis and the affordability of premiums with additional benefits. SMBs continue to contact us, and their views on employee legal cannabis use have become more relaxed. And rightly so, when precedence was set in the New Jersey Supreme Court ruling, where employees who legally use cannabis as permitted by the states Compassionate Use of Cannabis of Medical Marijuana Act cannot be fired.
The authenticity of cannabis benefits in employee health plans gives Novus the ability to capture more value from selling individual policies to the economics of selling to the multitudes.
Expansion Of Partnerships
Partnerships continue to increase with agreements with Health Carriers, Third-party Administrators, Pharmacy Benefits Managers, Professional Employment Organizations, and Brokers in Group Sales. These partnerships encompass adding cannabis benefits as a rider and/or as a supplement bundle to consumer health plans. They see how Novus benefit packages are an enticement to acquire new clients and up-sell existing ones.
The unique characteristics of our business model is based on the acceptance of cannabis being a benefits package to health plans. According to Forbesby 2025, 5.4 million Americans, or 2.4% of U.S. adults, will be registered patients in medical cannabis states.
However, that 2.4% will considerably increase as the price of cannabis proliferates with added state/federal taxation to recreational products, alluring rec users to seek health plans that include cannabis. The success of our business model is making cannabis affordable to our patient /members by reducing the cost of the plant by 30%-35% combined with a 15%-17% abatement in taxes at the point of sale.
Illicit Cannabis Market
Recently California authorities eradicated 509,453 plants from 135 sites in the past 13-weeks with an undisclosed report of how much the operation cost the state government. We continue to advise cannabis verticals and state officials on using Novus insurance plans to cost-effectively combat illicit cannabis which will top $4 billion by 2025 as reported by New Frontier Data.
These entities will quickly understand that by utilizing Novus insurance plans how compliantly we will corral med and rec users towards legal brands, we are confident that it is clearly discernable that this methodology is far superior to expensive law enforcement measures.
Provider Network
Our Provider network covers over 20,000 zip codes. The expansion of our Provider network is a continuous effort to develop underserved markets despite the slow down due to COVID. The procurement of reliable cannabis verticals as a Provider is the most arduous and nonlinear undertaking in our business model and it will be the same for any new competition. Having a head start as far back as 2016, we believe, we will leave very little resources to potential rivals in this department.
Financial Highlights
Financial milestones within the third quarter of 2021:
No Dilution: No common stock was issued
Three Month Revenue Increase: $6,656 or 9.8% to $67,955 for the three months ended September 30, 2021, as compared to $61,299 for the three months ended September 30, 2020.
Six Month Revenue Increase $11,477 or 8.8% to $132,686 for the six months ended September 30, 2021, as compared to $121,209 the six months ended September 30, 2020.
Profit Margin: Demonstrated a 36% profit margin pricing structure in its business model for the three months ended September 30, 2021
Net Income Increase: $4,202 or 17% to $24,888 for the three months ended September 30, 2021, as compared to $20,686 three months ended September 30, 2020
Shareholder Equity Increase: $1,481,889 on September 30, 2021, from $1,465,967on September 30, 2020
Cash and Cash Equivalents Increase: Moderately from $157,888 on September 30, 2020, to $158,195 three months ended September 30, 2021. Due to the cost of integrating Novus and PRAM back-office data to support their newly acquired clientele.
Cash Flow: Increased 16% to $48,968 for the six months ended September 30, 2021, as compared to $41,270 the six months ended September 30, 2020.
Conclusion
Frank Labrozzi, CEO states, We are fervent as we make cannabis health insurance mainstream. The acceptance of cannabis in employer-sponsored health plans combined with the inclusion of our benefits into health carriers plans makes the first-mover advantage of our infrastructure a successful perspective towards the value of our insurance model.
Research Novus:
Financial Filings: Click Here
Quote: Click Here
Website: Click Here
Investor's Page: Click Here
AskMuncher
4 years ago
$NDEV Novus Hires Insurance Industry Powerhouse Executive to Accelerate Growth
Press Release | 06/15/2020
30-Year Insurance Executive to Lead Expansion Efforts
MIAMI, FL / ACCESSWIRE / June 15, 2020 / Novus Acquisition and Development, Corp. (OTC PINK:NDEV), through its wholly-owned subsidiary WCIG Insurance Services, LLC., is the nation's first health carrier offering cannabis health plans to recreational and medicinal users, is pleased to announce the hiring of Mark Kuban to the Novus Cannabis MedPlan team.
Mark Kuban comes to Novus as a 30-year insurance executive, having previously worked with Colonial, Sun Life, and Washington National. His strengths are the creation of InsurTech innovation and streamlining the sale of carrier benefits to the consumer through the agent/broker network.
Mr. Kuban, stated, "I am passionate about the cannabis sector when I became familiar through my advisory work with the United States Cannabis Chamber of Commerce. My focus at Novus will be to accelerate sales growth by increasing broker/agent recruitment, greater alignment with InsureTech companies that retain millions of consumers and employ executives to administer group sales."
Mr. Kuban's most notable accomplishment were:
A & H marketing arm for AIG, that facilitated the alteration of the profitability framework from Tech fee's to Commission/admin fee's, tripling policy margins.
At Colonial Life he implemented sales and marketing programs that increased broker sales throughout fifteen states in the Midwest.
Developed a New Consumer Centric enrollment platform for Sun Life.
A skilled keynote speaker covering industry topics relating to ACA compliance, transparency, and promotion of benefits in health insurance.
Sits on the Advisory Board of National Cannabis Industry Association for Insurance regulation and management.
Novus CEO Frank Labrozzi, commented, "Mr. Kuban's significant experience has the right skill set to help support our expansion goals as well as the commitment to excellent service that is a hallmark of our Company. Mr. Kuban is a consummate professional with the ability to manage multiple stages of our growth environment and the development of Novus' ecosystem as we continue to gain market share as the nation's primary carrier of cannabis health plans."
Recap First Quarter 2020 Financial Highlights:
Revenue increased $7,403 or 14% to $59,077 for the three months ended March 31, 2020, as compared to the three months ended March 31, 2019
Demonstrated a 34% profit margin pricing structure in its business model for the three months ended March 31, 2020
Net income increased $2,828 or 16% to $20,308 for the three months ended March 31, 2020, as compared to the three months ended March 31, 2019
No dilution to the total shares outstanding this reporting period, with no insider sales
Shareholder equity remained strong with an increase to $1,445,891 at March 31, 2020, from $1,426,431 at December 31, 2019
Cash and Cash Equivalents increased to $152,968 at March 31, 2020, from $149,822 at December 31, 2019
Increased Zip Code Availability In Our Network Provider Coverage Area
Executed Contract With Mark Kuban To Head Broker Relations
Continued to Ramp with Managing General Agency (MGA) with Healthfield Solutions, LLC
Due Diligence Review
Financial Filings: Click Here
Quote: Click Here
Website: Click Here
Investor's Page: Click Here
How Insurance Companies are Valued: Click Here
Media Coverage: Click Here
About Novus
Novus Acquisition & Development Corp. (NDEV), through its subsidiary WCIG Insurance, provides health insurance and related insurance solutions within the wellness and medical marijuana industries in states where legal programs exist. Novus has developed its infrastructure within many lines of the insurance business such as health, property & casualty, life, accident, and fixed annuities.
Novus' medical cannabis benefits package will work as outside developers and will not cultivate, handle, transport grow, extract, dispense, put up for sale, put on the market, vend, deliver, supply, circulate, or trade cannabis or any substances that violate the United States law or the Controlled Substances Act, nor does it intend to do so in the future and will continue to follow state and federal laws. The statements made about specific products have not been evaluated by the United States Food and Drug Administration (FDA) and are not intended to diagnose, treat, cure or prevent disease. All information provided on these press releases or any information contained on or in any product label or packaging is for informational purposes only and is not intended as a substitute for advice from your physician or other health care professional. Once a push notification is competed the transaction is solely between the state-licensed dispensary and the registered patient.
The state laws are in conflict with the federal Controlled Substances Act. The current administration has effectively stated that it is not an efficient use of resources to direct federal law enforcement agencies to prosecute those lawfully abiding by state-designated laws, allowing the use and distribution of medical marijuana. However, there is no guarantee that the current administration, nor any future administration, will not change this policy and decide to enforce the federal laws strongly. Any such change in the federal government's enforcement of current federal laws could cause significant financial changes to Novus Medical Group. While we do not intend to harvest, distribute or sell cannabis or cannabis related products, we may be harmed by a change in enforcement by federal or state governments.
Forward-Looking Statements
This release includes forward-looking statements, which are based on certain assumptions and reflects management's current expectations. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. Some of these factors include: general global economic conditions; general industry and market conditions and growth rates; uncertainty as to whether our strategies and business plans will yield the expected benefits; increasing competition; availability and cost of capital; the ability to identify and develop and achieve commercial success; the level of expenditures necessary to maintain and improve the quality of services; changes in the economy; changes in laws and regulations, includes codes and standards, intellectual property rights, and tax matters; or other matters not anticipated; our ability to secure and maintain strategic relationships and distribution agreements. Novus disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Contact Information
p855-228-7355
Email: info@getnovusnow.com
SOURCE: Novus Acquisition and Development, Corp.
Level up your trading with our powerful tools and real-time insights all in one place.
j03
3 months ago
jjr04001
3 months ago
NHPIPIXiPY$26
6 months ago
Killinit272
1 year ago
Floppyplants
4 years ago
Caveat Emptor
4 years ago
chico hombre2
5 years ago
Hot Features
Premium
